VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker ProfilingGlobeNewsWire · 3 days ago
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsGlobeNewsWire · Oct 7, 2026
VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head ComparisonDefense World · Sep 30, 2026
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCsGlobeNewsWire · Sep 16, 2026
VivoSim Labs to Add Rat Liver Model to NAMkind PlatformGlobeNewsWire · Sep 1, 2026
VivoSim Provides Financial and Listing Compliance UpdateGlobeNewsWire · Aug 6, 2026VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.